References
- Rachelefsky G S, Kats R M, Sigel S C. Albuterol syrup in the treatment of the young asthmatic child. Ann Allergy 1981; 47: 143
- Lonnerholm G, Foncard T, Lindstrom B. Dose, plasma concentration and effect of oral terbutaline in long-term treatment of childhood asthma. J Allergy Clin Immunol 1984; 73: 508
- Dahl R, Harwing H, Henriksen J, Ronne K, Scholer P. Procaterol and terbutaline in bronchial asthma: a double blind, placebo controlled, cross over study. Allergy 1985; 40: 501
- Paterson J W, Woolkock A J, Shenfield G M. Bronchodilator drugs: state of the art. Am Rev Respir Dis 1979; 120: 1149
- Engelhardt G. Pharmakologisches wirkunghprofil von NAB 365 (clenbuterol), einem neuen broncholytikum mit einer selektiven wirkung auf die adrenergen beta2rezeptoren. Arzneim-Forsch (Drug Res) 1976; 26: 1404–1420
- Zimmer A. Einmalapplikation, mehrfachapplikation und metaboliten-muster von clenbuterol bei menschen. Arzneim-Forsch (Drug Res) 1976; 26: 1446–1450
- Blom-Bulow B, Boe J, Bulow K, Hagelquist I. A comparison of oral β2-agonists clenbuterol and salbutamol in obstructive lung disease, a double blind cross-over study. Curr Ther Res 1985; 37: 51–57
- Dorow P. Mono- und kombinationstherapie bei chronisch obstruktiver bronchitis. Der einfluss einer mono- und kombinationstherapie auf die totale resistance bei patienten mit chronisch obstruktiver bronchitis. Z Allg Med 1979; 55: 259–262
- Cummiskey J, Keelan P, Gray P, Cox G A. Comparison of NAB 365 and salbutamol tablets in chronic bronchitis and asthma. J Irish Med Assoc 1978; 71: 123–126
- Girbino G, Giacobbe G, Andò F, Daniotti S, Schiassi M. Long-term post marketing surveillance of clenbuterol. Eur J Respir Dis 1986; 69(suppl 146)68
- Boner A, Bennati D, Castellani C, Schiassi M. Dose response study of oral clenbuterol in asthmatic children. Pediatr Pulmonol 1987; 3: 34
- Crowe M J, Counithan H E, O'Malley K. A comparative study of a new selective β2-adrenoceptor agonist, procaterol and salbutamol in asthma. Br J Clin Pharmacol 1985; 79: 787–791
- Zanetti C L, Rotman H H, Dresner A J. Efficacy and duration of action of procaterol, a new bronchodi-lator. J Clin Pharmacol 1982; 22: 250–253
- Siegel S C, Katz R M, Rachelefsky G S, Brandon M L, Bargen L A. A placebo-controlled trial of procaterol: A new long-acting oral beta2-agonist in bronchial asthma. J Allergy Clin Immunol 1985; 75: 698
- Ekwo E, Weinberger M. Evaluation of a program for the pharmacologic management of children with asthma. J Allergy Clin Immunol 1978; 67: 240
- Polgar G, Promadhat V. Pulmonary Function Testing in Children: Techniques and Standards. W.B. Saunders, Philadelphia 1971; 42–86
- Cochran W G, Cox G M. Experimental Designs, 2nd ed. John Wiley, New York 1966
- Muers M F. Diurnal variation in asthma. Arch Dis Child 1984; 59: 898
- Castellani C, Boner A L. Asthma and circadian rhythms. Ital J Pediatr 1985; 72: 793
- Terho E O, Tukiainen H, Jaakkola J, Torkko M. Comparison between oral procaterol and salbutamol in patients with asthma. In XXII Congress of the European Academy of Allergology and Clinical Immunology, Budapest, May 4–10, 1986